AVEO Pharmaceuticals, Inc. (AVEO) Reports In-Line Q3 Loss; Revs Light

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) reported Q3 loss of ($0.55), in-line with the analyst estimate of ($0.55). Revenue for the quarter came in at $3.59 million versus the consensus estimate of $7.13 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c